Veradigm Inc. (NASDAQ:MDRX – Get Free Report) has been assigned an average rating of “Hold” from the six ratings firms that are covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $12.00.
MDRX has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $10.00 target price (down from $15.00) on shares of Veradigm in a report on Tuesday, March 19th. TD Cowen decreased their target price on shares of Veradigm from $26.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, May 28th. Finally, StockNews.com initiated coverage on shares of Veradigm in a report on Wednesday, June 26th. They issued a “hold” rating on the stock.
View Our Latest Stock Analysis on MDRX
Institutional Investors Weigh In On Veradigm
Veradigm Price Performance
MDRX stock opened at $9.66 on Wednesday. Veradigm has a 12 month low of $5.01 and a 12 month high of $14.09. The company’s 50-day moving average price is $8.64 and its two-hundred day moving average price is $8.63.
About Veradigm
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Recommended Stories
- Five stocks we like better than Veradigm
- When to Sell a Stock for Profit or Loss
- RXO Shares Surge Following New Acquisition Deal
- 10 Best Airline Stocks to Buy
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- The How and Why of Investing in Gold Stocks
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Veradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradigm and related companies with MarketBeat.com's FREE daily email newsletter.